Omalizumab for treatment of anti-GD2 antibody-related urticaria Journal Article
| Authors: | Glincher, R.; Lentini-Rivera, A.; Jones, L. A.; D'Andrea, L.; Durney, C.; Kasper, C.; Lin, Y.; Shrager, L.; Markova, A.; Lacouture, M.; Modak, S. |
| Article Title: | Omalizumab for treatment of anti-GD2 antibody-related urticaria |
| Abstract: | Outcomes for high-risk neuroblastoma have improved with the addition of antidisialoganglioside (GD2) antibody-mediated immunotherapy to multimodality therapy. Urticaria is an expected side effect of anti-GD2 immunotherapy. Rarely, despite maximal use of antihistamines and H2 receptor antagonists, refractory urticaria can result in impaired quality of life, and delays or discontinuation of immunotherapy. The anti-IgE monoclonal antibody, omalizumab, is approved for the treatment of asthma and chronic spontaneous urticaria. We successfully managed grade 3, naxitamab-related urticaria refractory to standard management in 2 patients using omalizumab, allowing for continued anti-GD2 immunotherapy. Omalizumab did not impact antitumor activity or immunogenicity of naxitamab. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | child; clinical article; preschool child; school child; child, preschool; unclassified drug; case report; drug withdrawal; temozolomide; quality of life; multiple cycle treatment; phase 2 clinical trial; bone marrow; granulocyte macrophage colony stimulating factor; antineoplastic activity; high risk patient; irinotecan; immunology; neuroblastoma; immunogenicity; outcomes research; methylprednisolone; asthma; drug therapy; urticaria; antihistaminic agent; diphenhydramine; premedication; immunoglobulin e; gangliosides; ganglioside; histamine h2 receptor antagonist; ganglioside, gd2; ganglioside antibody; hydroxyzine; loratadine; famotidine; chemoimmunotherapy; cetirizine; humans; human; male; female; article; immunoglobulin antibody; dinutuximab; omalizumab; naxitamab; anti-allergic agents; anti disialoganglioside antibody; antiallergic agent |
| Journal Title: | Journal of Pediatric Hematology/Oncology |
| Volume: | 46 |
| Issue: | 7 |
| ISSN: | 1077-4114 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2024-10-01 |
| Start Page: | e531 |
| End Page: | e533 |
| Language: | English |
| DOI: | 10.1097/mph.0000000000002939 |
| PUBMED: | 39177945 |
| PROVIDER: | scopus |
| PMCID: | PMC12103884 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Shakeel Modak -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work